Plain-English translation of NCT05405387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called budesonide can help prevent severe diarrhea in patients with multiple myeloma who are undergoing a stem cell transplant. Diarrhea is a common and sometimes serious side effect of this type of transplant. The study will compare patients who take the medication to those who receive a placebo (a dummy pill with no active ingredient) to see if the treatment reduces diarrhea.
Severe diarrhea is a frequent and uncomfortable complication after stem cell transplant that can interfere with recovery and quality of life. Researchers want to know whether this medication, which reduces inflammation in the gut, might help prevent or reduce this problem.
You likely qualify if…
You likely don't qualify if…
You would first enter a 20-person safety phase where all participants take the medication for about 18 days while your new stem cells start working. After that phase, if it's safe to continue, you would be randomly assigned to either receive the medication or a placebo three times a day by mouth. You would report any diarrhea and other side effects through a patient survey, and researchers would monitor your recovery and engraftment (when your new blood cells start functioning).
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States